Alesheim, Switzerland

Doriano Fabbro


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Doriano Fabbro: Innovator in Leukemia Treatment

Introduction

Doriano Fabbro is a notable inventor based in Alesheim, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of leukemia. His innovative approach has the potential to improve the lives of many patients suffering from this challenging condition.

Latest Patents

Doriano Fabbro holds a patent for a method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias. The patent describes a method that involves administering a therapeutically effective amount of a staurosporine derivative, specifically PKC412 or a pharmaceutically acceptable salt thereof. This treatment can be used alone or in combination with other therapeutic measures. The patent also covers the use of a staurosporine derivative for preparing a medicament for the treatment of MLL rearranged ALL, along with a commercial package that includes instructions for its use.

Career Highlights

Fabbro is associated with the Dana-Farber Cancer Institute Inc., where he continues to work on innovative solutions for cancer treatment. His research focuses on developing effective therapies for leukemia, contributing to advancements in oncology.

Collaborations

Throughout his career, Doriano Fabbro has collaborated with esteemed colleagues, including James Douglas Griffin and Scott A Armstrong. These partnerships have fostered a collaborative environment that enhances research and development in cancer treatment.

Conclusion

Doriano Fabbro's work in the field of leukemia treatment exemplifies the impact of innovation in medicine. His patented methods and ongoing research hold promise for improving patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…